Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Scientists scan brains of people with depression and bipolar disorder to spot key differences

NCT ID NCT03898297

Knowledge-focused Sponsor: Yale University Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Sep 04, 2026 · Updated 2 times

Summary

This study used brain scans to look at two things in people with depression or bipolar disorder: a glutamate receptor called mGluR5 and the density of connections between brain cells (synapses). Researchers compared 120 participants, including healthy volunteers, using PET and MRI scans. The goal was to better understand how these brain features differ in mood disorders, which could guide future treatments.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

79 people

The number who actually took part.

Started

Jan 2017

Finished

Oct 2024

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

60 psychiatrically-healthy controls 30 MDD 30 bipolar

Ages

18 to 80 years

Sex

Anyone

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * General inclusion criteria: 18-80 years old English speaking -Inclusion criteria for healthy controls: no current, or history of any DSM-5 diagnosis * Inclusion criteria for MDD subjects clinical diagnosis of major depressive disorder * Inclusion criteria for bipolar subjects clinical diagnosis of bipolar disorder Exclusion Criteria: * Current or past significant medical, neurological, or metabolic disorder * history of head injury that led to significant long term decline in cognitive abilities as seen by decline in grades or work performance * history of significant medical illness such that would contraindicate study participation based on above criteria and PI/MD history review * Active, significant suicidal ideation * Implanted metallic devices or any MR contraindications * women who are pregnant or breastfeeding * Met Diagnostic and Statistical Manual of Mental Disorders(DSM)-5 criteria for mild substance use disorder in the past 6 months or moderate to severe substance use disorder within the past year (except marijuana or nicotine) * history of prior radiation exposure for research purposes within the past year such that participation in this study would place them over FDA limits for annual radiation exposure. This guideline is an effective dose of 5 rem received per year * Current, past, or anticipated exposure to radiation in the work place within one year of proposed research PET scans * Blood donation within 8 weeks of the start of the study * History of a bleeding disorder or currently taking anticoagulants (such as Coumadin, Heparin, Pradaxa, Xarelto)

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Bipolar disorder are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

bipolar disorder Depression major depressive disorder mood disorder

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Bipolar disorder Healthy Major depressive disorder

Contacts and locations

Locations

  • Yale University PET Center

    New Haven, Connecticut, 06519, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.